
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists assist in controlling type 2 diabetes by stimulating insulin secretion after meals and limiting glucose production by the liver, both of which contribute to lower blood sugar levels. They are often used when first line oral therapies such as metformin no longer provide sufficient control or when additional risk reduction is needed. Some members of this drug class have additionally been shown to reduce the likelihood of cardiovascular events in patients with type 2 diabetes who already have heart issues.
For people without diabetes, GLP-1 agonists including Wegovy and Saxenda are approved by the FDA for long term weight management. These drugs work on the brain’s appetite centers to enhance feelings of fullness and decrease hunger, helping patients naturally cut back on calories without extreme dieting. Studies show that when GLP-1 therapy is paired with healthy eating and regular physical activity, many individuals experience significant and sustained weight loss.
GLP-1 receptor agonists support glycemic control by enhancing insulin secretion when food is consumed and by dialing down glucagon, the hormone that raises blood sugar. This dual action helps smooth out post meal spikes in blood glucose and leads to better long term balance. Since their effects are largely activated only when glucose levels are elevated, the chance of hypoglycemia is reduced compared with many standard diabetes medications.
GLP-1 therapy is known for its ability to help patients achieve weight loss that can be sustained over time, rather than temporary results. By slowing gastric emptying and activating brain pathways that increase feelings of fullness, GLP-1 medications help curb appetite and reduce overall food intake. Evidence from clinical studies shows that treatments like liraglutide, semaglutide, and tirzepatide are associated with meaningful and persistent weight loss when combined with diet and exercise changes.



GLP-1/GIP co-agonists activate both GLP-1 and GIP receptors, which boosts insulin production and improves appetite control more effectively than GLP-1 alone. This dual-action approach provides a more potent solution for managing blood sugar and hunger, making them highly effective for treating obesity and type 2 diabetes.
GLP-1/glucagon co-agonists target both GLP-1 and glucagon receptors, promoting weight loss and improving energy metabolism while helping to preserve lean muscle mass, making them a balanced approach to improving metabolic health.
You may want to consider GLP-1 therapy if:

